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Abstract
Background/Aim: Tobacco use reduces the effect of non-surgical periodontal
therapy. Host-modulation with low-dose doxycycline (LDD) might favour repair and
promote an improved treatment response. The aim of this study was to investigate the
effect of LDD in smokers on non-surgical periodontal therapy.
Material and Methods: This was a parallel arm, randomized, identical placebo-
controlled trial with masking of examiner, care-giver, participant and statistician and 6
months of follow-up. Patients received non-surgical therapy and 3 months of test or
control drug. Statistical analysis used both conventional methods and multilevel
modelling.
Results: Eighteen control and 16 test patients completed the study. The velocity
of change was statistically greater for the test group for clinical attachment level
 0.19 mm/month (95% CI 5  0.34, 0.04; p 5 0.012) and probing depth 0.30 mm/
month (95% CI 5  0.42,  0.17; po0.001). However, no differences were observed
for absolute change in clinical or biochemical markers at 6 months.
Conclusions: This study does not provide evidence of a benefit of using LDD as an
adjunct to non-surgical periodontal therapy in smokers.
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Tobacco use has a major influence on
periodontal therapy. A reduction in clin-
ical benefits in smokers following non-
surgical periodontal therapy is a consis-
tent finding across many studies (Preber
& Bergstrom 1986, Bostrom et al. 1999,
Palmer et al. 1999a, Kinane & Chestnutt
2000, Labriola et al. 2005). The sug-
gested mechanisms for this finding
include inflammatory, immunological,
microbiological and wound-healing
phenomena (Palmer et al. 1999b,
Kinane & Chestnutt 2000).
Upregulation of inflammation has
been strongly implicated in the impaired
response with increased gingival levels
of the pro-inflammatory cytokine
tumour necrosis factor-a (TNF-a) in
smokers compared with non-smokers
(Bostrom et al. 1999, Palmer et al.
1999b, Kinane & Chestnutt 2000). In
addition, lower levels of regulators of
tissue breakdown have been found such
as protease inhibitors (e.g. a-1-antitryp-
sin and a-1-macroglobulin) in the gingi-
val fluid of smokers than non-smokers
(Kinane & Chestnutt 2000). Whichever
arm(s) are activated, the net result will
be an increase in matrix metalloprotei-
nases, leading to periodontal destruction
and this might be further exacerbated by
the finding of increased levels of serum-
soluble inter-cellular adhesion mole-
cule-1 (sICAM-1) in smokers. The few
studies that have used objective markers
of smoking exposure have demonstrated
a significant correlation between serum
cotinine (COT) levels and both sICAM-
1 levels and attachment loss (Palmer
et al. 1999b).
Biochemical measures of tobacco use
have developed from concerns that self-
reported tobacco data may give inaccu-
rate information on the magnitude of
‘‘tobacco exposure’’ (Jarvis et al. 1987).
Biochemical analyses of tobacco use
include nicotine metabolites (e.g. in
saliva) and exhaled carbon monoxide
(CO) (Jarvis et al. 1987, Barnfather
et al. 2005), although no gold standard
currently exists (Needleman et al. 2006).
While quitting tobacco use is impor-
tant for general and oral health, only a
minority of tobacco users will quit at
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any one time (Needleman et al. 2006).
In view of this consistent finding, devel-
oping methods to improve the perio-
dontal treatment response of tobacco
users unable to quit is important as the
prevalence of both tobacco use and
periodontitis remains high. If smoking
enhances connective tissue breakdown
in periodontitis, one novel therapeutic
approach might be to inhibit metallo-
proteinase (MMP) activity as has been
demonstrated for tetracyclines (Golub
et al. 1997). Well-evaluated markers of
collagen turnover, such as the pyridino-
line cross-linked carboxyterminal telo-
peptide of type I collagen (ICTP), have
been used to investigate changes in bone
breakdown and bone turnover (Sarment
et al. 2006). ICTP was reduced in
patients with periodontitis following
administration of low-dose doxycycline
(LDD) and with no effect on non-treated
subjects.
Clinical trials of LDD in humans
have shown an improved healing fol-
lowing non-surgical periodontal therapy
(Caton et al. 2000). A subgroup analysis
of smokers, combining data from two
trials of LDD, has suggested improved
clinical healing in smokers receiving the
active drug compared with placebo (Pre-
shaw et al. 2005). However, these ana-
lyses were not direct comparisons based
on the original randomization scheme
and may therefore be subject to bias.
Clarification of this hypothesis is there-
fore needed.
With respect to designing periodontal
clinical trials, multiple data points per
outcome for each subject at each visit
are collected. It is unreasonable to treat
observations for each periodontal site as
independent, statistically speaking,
which is why patient-based opposed to
site-based analyses have been recom-
mended (Imrey 1986). However, such
analytical methods lose valuable infor-
mation where more than one site per
subject is studied. Methods such as
multilevel modelling may be used to
analyse the behaviour of repeated mea-
sures of individual sites while acknowl-
edging that these are grouped by teeth
and nested within subjects (Gilthorpe
et al. 2000, 2001). This allows for a
much deeper understanding of the site-
specific changes induced by therapy
(Gilthorpe et al. 2003).
Therefore, the aim of this study was
to investigate the effect of a novel
approach to modulating the healing
response of smokers to periodontal ther-
apy using LDD as an adjunct to non-
surgical therapy in smokers unable to
quit tobacco use. The hypothesis was
that host modulation might improve the
clinical outcome of treatment. A further
aim was to examine the use of multi-
level modelling as a tool in the analysis
of periodontal clinical trial data.
Material and Methods
This was a parallel arm, randomized,
identical placebo-controlled trial with
masking of examiner, care-giver, parti-
cipant and statistician, with 6 months of
follow-up. The study examined the
effect of host-modulation by LDD as
an adjunct to non-surgical periodontal
therapy in current smokers.
Study sample size
The primary outcome was clinical
attachment level (CAL). Study sample
size calculations were based on subject-
level analyses (t-tests of aggregate mean
scores at a single follow-up) as the study
randomized individuals. Under the alter-
native hypothesis, a mean difference in
the observed CAL between groups of
1 mm, with a standard deviation (SD) of
1 mm, would require 16 or 22 indivi-
duals in each group to detect a signifi-
cant difference at the 5% level with 80%
or 90% power, respectively. With multi-
ple follow-up measures and the inten-
tion-to-analyse sites within a multilevel
framework, study-size estimates based
on subject-level t-tests were anticipated
to be overly conservative. Conse-
quently, while the study sought to
recruit up to 22 individuals per group,
achieving 16 and 18 in the treatment
and control groups, respectively, was
deemed satisfactory. Recruits were
patients referred to the Unit of Perio-
dontology, UCL Eastman Dental Insti-
tute, from September 2002 until August
2003.
Patient selection
The inclusion criteria were as follows:
age 30–70 years, at least 16 teeth pre-
sent, diagnosis of chronic periodontitis,
at least two teeth with probing depth
(PD) of X6 mm and at least 30% bone
loss in at least two quadrants excluding
third molars, current smoker of at least
10 cigarettes per day for a minimum of
1 year. Exclusion criteria were: allergy
to tetracycline, antibiotic prophylaxis
required before periodontal therapy, dai-
ly consumption of non-steroidal anti-
inflammatory drugs or antibiotics and
pregnancy or lactation and any health
condition potentially affecting the
response to periodontal therapy (e.g.
diabetes mellitus).
All potentially eligible subjects were
given brief smoking cessation interven-
tions including advice about the nega-
tive effect of smoking on general and
periodontal health and the importance of
stopping smoking to achieve periodontal
health. Individuals were asked whether
they were planning to quit in the next 6
months and those declining to quit were
invited to participate in the study. The
study was approved by the Ethics Com-
mittee of the Eastman Dental Hospital
(Reference 01/E012), and informed con-
sent was obtained from all patients. The
study was prospectively registered on
the Current Controlled Trials Register in
October 2002 (ISRCTN11033714).
Treatment allocation
Assignment to test (LDD) or control
(inactive identical placebo) group was
random. The sequence was computer
generated in blocks of four by the
research coordinator. Randomization
was concealed by the use of sequentially
numbered, identical containers contain-
ing active or identical-appearing place-
bo medication. The randomization code
was held centrally by the research coor-
dinator remote from the study and was
not broken until completion of the data
analyses.
Outcome assessment
The primary outcome was change in
the CAL. CAL was recorded from
the cemento-enamel junction (CEJ) to
the base of the probing pocket using a
graduated UNC-15 probe (Hu Friedy,
Chicago, IL, USA). Where the CEJ was
absent or unclear, an alternative land-
mark was selected and used for all
subsequent recordings. A single trained
and calibrated examiner, an experienced
dentist (GSG), was used throughout the
trial and performed all clinical measure-
ments. The calibration included dupli-
cate full-mouth assessment of 10
patients with disease severity similar to
those included in the trial. For PPD,
98.4% of sites were within 2 mm and
the corresponding values for gingival
margin (GM) and CAL were 97.5% of
sites and 99.3% of sites.
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Gingival crevicular fluid (GCF) was
sampled for ICTP (terminal carboxytelo-
peptide of type 1 collagen) at the eight
mesiobuccal sites per patient with the
initially deepest PDs with the same sites
sampled throughout the study. GCF ICTP
was collected on standardized filter paper
strips (Periopaper, OraFlow, Plainview,
NY, USA). Strips were gently inserted
into the gingival crevice until slight resis-
tance was felt and left for 15 s. Samples
were kept on ice before transfer to a
freezer at  201C. Samples were stored
and then transferred to the University of
Michigan for analysis. Frozen samples
were thawed at room temperature and
the proteins were then eluted through
centrifugation 5  in 12  75 ml poly-
propylene tubes at 2060 g for 5 min. with
20ml phosphate-buffered saline (pH 7.4)
containing 15 nM aprotinin, 1 mM PMSF
and 0.1% of human serum albumin as
described previously (Giannobile et al.
1995). GCF ICTP levels were quantified
using a radioimmunoassay (RIA) (Dia-
Sorin Inc., Stillwater, MN, USA) as
described previously (Risteli
et al. 1993). ICTP was determined as
total amount/time of collection (pg/site/
patient).
Secondary outcomes included PD,
gingival recession and bleeding on prob-
ing (BoP) recorded at six sites per tooth
with the manual probe and ICTP.
Explanatory variables that were
recorded were plaque (presence or
absence to a probe at the GM at six sites
per tooth) and measures of smoking
exposure, assessed in the following
ways: self-reported smoking history,
number of cigarettes smoked per day,
and number of years smoked, exhaled
CO (Smokerlyser, Bedfont Scientific
Ltd, Rochester, Kent, UK) and salivary
COT. For salivary COT, a dental cotton
roll was placed in the mouth until satu-
rated with saliva. It was then placed
in a 10-ml syringe and the saliva
was expressed into a 5 ml vial. The vial
was stored at  201C. Salivary COT was
assayed by the gas–liquid chromatogra-
phy method (detection limit 0.1 ng/ml)
(Feyerabend & Russell 1990). This assay
has been used widely in previous studies
(Jarvis et al. 1987, Smith et al. 1998).
Patient compliance and adverse
events were also recorded at each visit.
Treatment
Non-surgical periodontal therapy was
provided to all patients by an experi-
enced periodontist (RT). Therapy con-
sisted of up to four visits (total 4 h) of
oral hygiene instructions (including
modified Bass toothbrushing, inter-den-
tal cleaning with dental floss or inter-
dental brushes as appropriate) and scal-
ing and root planing of all supragingival
and subgingival deposits of plaque and
calculus, using both hand and ultrasonic
instruments and local anaesthetic as
needed. There was no limit to time for
debridement during the 4 h of available
appointment time, although the duration
of debridement was not recorded. At the
first treatment visit, test drug or placebo
was provided and the need for adherence
with both oral hygiene and drug use was
emphasized. The test drug was 20 mg
doxycycline (Periostat, CollaGenex
Pharmaceuticals, Newtown, PA, USA)
twice daily for 3 months. The placebo
was identical, with the exception of
omission of doxycycline. Enough drug
was dispensed for 1 month and re-
supplied at follow-up visits. Adherence
to drug use was examined by asking the
participants and also by the return of
drug containers.
Follow-up
At each recall visit, supportive perio-
dontal therapy was provided including
monitoring and advice in oral hygiene
and removal of all supra- and subgingi-
val deposits. All clinical, biochemical
and smoking exposure parameters were
recorded at each visit. Patients were
recalled following completion of ther-
apy at 1, 3 and 6 months.
Statistical methods
All data were entered into an Excel
spreadsheet, and then imported into the
statistical package R (version 2.1.1) for
validation (meticulously trawled for tran-
scription errors and inconsistencies
against a range of criteria), manipulation
(for structures appropriate for subsequent
analyses) and summary/aggregate ana-
lyses [e.g. analysis of covariance (ANCO-
VA) of the subject-level means], before
exporting to the multilevel software pack-
age MLwiN (version 2.02) for multilevel
modelling. Only sites with initial
PDX5 mm were included in the statisti-
cal analyses, as shallower sites did not
receive root planing, although they were
treated with subgingival scaling.
ANCOVA was used for the aggregate
data analyses as randomization ensured
sufficiently balanced subject-level base-
line mean outcomes. As sites were not
randomized, and there were substantial
site-level differences in means between
groups, multilevel ANCOVA analysis was
not deemed appropriate. A multilevel
time-series analysis was undertaken
instead, whereby site-level outcomes
from each occasion were modelled as
curvilinear ‘‘trajectories’’ over time.
These trajectories were then examined
in relation to several covariates. In addi-
tion to time (both linear and quadratic
components to reflect the curvilinear
nature of the outcome trajectories), the
covariates considered were group (treat-
ment/placebo), smoking history and
interactions between these covariates
and the time covariates. The interactions
between group and time determined
whether treatment effects over time dif-




Thirty-five subjects were recruited,
although one withdrew before allocation
of treatment group and was therefore not
included in the study (Fig. 1). Conse-
quently, 34 subjects were included in
the analysis (18 control, 16 test), with an
age range of 32–58 years at baseline.
Four subjects did not complete the study
(two in each group). Three subjects did
not return due to personal problems and
one due to loss of interest in the study.
An intention-to-treat analysis used a last
observation carried forward.
The age range of the participants was
32–50 years. The placebo group was
slightly younger, with a mean birth
year of 1957.8 [standard deviation
(SD) 5 6.1], than the Periostat group,
with a mean birth year of 1960.3
(SD 5 7.6), although both sexes were
similarly aged with males’ mean birth
year being 1959.8 (SD 5 6.6) and
females’ mean birth year being 1958.1
(SD 5 7.3). Baseline characteristics are
summarized in Table 1. Subjects within
groups were generally well matched at
baseline, with measures of tobacco
exposure being similar except for sali-
vary COT, which was slightly higher
in the placebo group. Clinically, a 10%
difference for BoP was also observed.
Effect of treatment
At 6 months, aggregate analyses (ANCO-
VA comparing subject-level mean values
of treated teeth) revealed that there were
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no significant differences in the clinical
improvements observed between groups
(Table 2). However, when these same data
were analysed using multilevel time-series
methods, there were significant differ-
ences between groups (Table 3).
For all outcomes, the modelled tra-
jectories were curvilinear, i.e. outcome
5 intercept1linear component  time
1quadratic component  time2, where
the linear component indicates change
in the outcome per unit change in time
(velocity), and the quadratic component
indicates change in the outcome per unit
squared in time (acceleration).
For the primary outcome of CAL and
subsidiary outcomes of PD, recession
and BoP, there were significant differ-
ences between the mean trajectories for
the test and placebo groups. For
instance, considering the interaction of
group with velocity (i.e. the linear time
interaction), CAL consistently reduced
more within the test than the control
group (Fig. 2), irrespective of whether
or not adjustment was made for smoking
exposure (either baseline or occasion-
specific); Models 1 and 2: difference in
mean velocity of CAL 5  0.19 mm/6
month (95% CI 5  0.34,  0.04;
p 5 0.012). The velocity of change was
thus greater in the treatment group than
the control group. However, divergence
between groups slowed, revealed by the
positive interaction of group with accel-
eration (i.e. the quadratic time interac-
tion). The rate of divergence was thus
not maintained and the reduction in
CAL was slowing for the treatment
group compared with the control group,
difference in mean acceleration of
CAL 5 0.38 mm/6 month2 (95%
CI 5  0.07, 0.83; p 5 0.097). When
adjustment was made for occasion-
specific smoking exposures (Model 3),
the interaction between group and
velocity was slightly more nega-
tive ( 0.22 mm/6 month; 95%
CI 5  0.41,  0.03; p 5 0.027) and
the interaction between group and
acceleration was more positive
(0.79 mm/6 month2; 95% CI 5 0.21,
1.36; p 5 0.008), indicating that for
Analysed (n=16) 
Excluded from analysis (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=N/A) 
Allocated to test intervention (n=17) 
Received allocated intervention (n=16)
Did not receive allocated intervention (n=1) 
Give reasons: Did not attend 
Lost to follow-up (n=0) 
Discontinued intervention (n=N/A) 
Allocated to control intervention (n=18)
Received allocated intervention (n=18)
Did not receive allocated intervention (n=18) 
Give reasons: NA
Analysed  (n=18)





Fig. 1. Patient flow through study.
Table 1. Baseline characteristics of subjects
Subject means (95% CI)
placebo (N 5 18) LDD (N 5 16) difference
Subjects
Smoking (years) 26.1 (13.0, 39.1) 24.4 (8.0, 40.9) 1.6 ( 3.6, 6.8)
Cigarettes (per day) 18.3 (7.0, 29.5) 16.7 (3.2, 30.2) 1.6 ( 2.7, 5.9)
COn (% volume) 5.0 ( 0.3, 10.2) 4.6 (0.0, 9.2) 0.4 ( 1.3, 2.1)
COn (ppm) 27.7 ( 0.8, 56.1) 25.3 ( 2.4, 52.9) 2.4 ( 7.2, 12.1)
Cotinine (ng/ml) 379.6 (0.0, 771.6) 327.2 (19.5, 634.9) 52.4 ( 69.9, 174.7)
Treated teeth/sites
PPD (mm) 5.79 (4.93, 6.65) 5.96 (4.92, 7.01)  0.17 ( 0.51, 0.16)
REC (mm)  0.12 ( 2.13, 1.89) 0.28 ( 1.82, 2.39)  0.41 ( 1.12, 0.30)
CAL (mm) 5.67 (3.52, 7.82) 6.25 (3.99, 8.50)  0.58 ( 1.34, 0.18)
BoPn (%) 76.3 (52.5, 100.1) 65.8 (21.7, 109.8) 10.5 ( 2.1, 23.1)
Plaquen (%) 76.8 (42.9, 110.8) 79.5 (37.6, 121.4)  2.7 ( 16.0, 10.6)
ICTPw (pg/site) 2.25 (0.00, 4750.76) 0.81 (0.00, 9279.67) 1.44 ( 1.95, 3.99)
nNot normally distributed hence means and 95% CIs have limited meaning.
wGeometric mean (i.e. natural logarithm taken before mean is calculated and inverse logarithm
applied afterwards).
CI, confidence interval; ICTP, carboxyterminal telopeptide of type I collagen; BoP, bleeding on
probing; CAL, clinical attachment level; CO, carbon monoxide; LDD, Low Dose Doxycycline.
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Model 3 divergence was initially greater
but then slowed more than observed for
Models 1 and 2.
PD reduced with greater velocity
within the test than the control group
(Fig. 3), irrespective of whether or not
adjustment was made for baseline
smoking exposure; Models 1 and 2:
difference in mean velocity of PD 5
 0.30 mm/month (95% CI 5  0.42,
 0.17; po0.001). Where adjustment
was made for occasion-specific smoking
exposure (Model 3), the interaction
between group and acceleration
revealed a significant slowdown of the
divergence between groups; Model 3:
difference in mean acceleration of
PD 5 0.71 mm/month2 (95% CI 5 0.27,
1.15; p 5 0.002). However, this finding
was not consistent with the models that
either adjusted for baseline smoking
exposure (Model 2) or where no adjust-
ment for smoking was made (Model 1).
For recession, during the study period
there was no significant difference in
outcome velocity between treatment and
control groups, whether or not adjust-
ment was made for baseline smoking
exposure; Models 1 and 2: difference in
mean velocity of REC 5 0.10 mm/month
(95% CI 5  0.01, 0.22; p 5 0.085).
However, this initially modest differ-
ence in velocity grew significantly;
Models 1 and 2: difference in mean
acceleration of REC 5 0.54 mm/month2
(95% CI 5 0.19, 0.89; p 5 0.003). When
adjustment was made for occasion-
specific smoking exposure (Model 3),
the velocity of change in recession was
Table 2. Results from a subject-level analysis of covariance of primary and subsidiary outcomes
Change in subject-level means (95% CI)
placebo (N 5 18) LDD (N 5 16) ANCOVA p-value
PPD (mm)  0.98 ( 2.17, 0.21)  1.40 ( 2.69,  0.11)  0.33 ( 0.71, 0.05) 0.103
REC (mm) 0.58 ( 0.40, 1.55) 0.76 ( 0.24, 1.76) 0.12 ( 0.20, 0.45) 0.461
CAL (mm)  0.40 ( 1.20, 0.39)  0.65 ( 2.13, 0.84)  0.23 ( 0.64, 0.18) 0.282
BoP (%)  27.2 ( 64.8, 10.4)  21.8 ( 59.7, 16.1)  2.0 ( 12.2, 8.1) 0.699
Plaque (%)  19.3 ( 67.0, 28.4)  21.7 ( 60.1, 16.7)  1.5 ( 15.5, 12.5) 0.834
ICTP (ln pg/site) 0.01 (0.00, 4307.44)n 0.02 (0.00, 5379.19)n 0.13 ( 3.78, 3.51)w 0.944
nGeometric mean change.
wDifference on the natural logarithm scale.
CI, confidence interval; ANCOVA, the mean difference in subject-level mean outcome at 6 months between treatment and placebo groups estimated by
analysis of covariance; ICTP, carboxyterminal telopeptide of type I collagen; BoP, bleeding on probing; CAL, clinical attachment level; LDD, Low Dose
Doxycycline.
Table 3. Results of multilevel time-series analysis of primary and subsidiary outcomes
Model 1 Model 2 Model 3
diff (95% CI) p-value diff (95% CI) p-value diff (95% CI) p-value
CAL
Velocity  0.19 ( 0.34,  0.04) 0.012  0.19 ( 0.34,  0.04) 0.012  0.22 ( 0.41,  0.03) 0.027
Acceleration 0.38 ( 0.07, 0.83) 0.097 0.38 ( 0.07, 0.83) 0.097 0.79 (0.21, 1.36) 0.008
PD
Velocity  0.30 ( 0.42,  0.17) o0.001  0.30 ( 0.42,  0.17) o0.001  0.38 ( 0.53,  0.24) o0.001
Acceleration  0.16 ( 0.54, 0.22) 0.417  0.16 ( 0.54, 0.22) 0.417 0.71 (0.27, 1.15) 0.002
REC
Velocity 0.10 ( 0.01, 0.22) 0.085 0.10 ( 0.01, 0.22) 0.085 0.18 (0.03, 0.33) 0.021
Acceleration 0.54 (0.19, 0.89) 0.003 0.54 (0.19, 0.89) 0.003 0.06 ( 0.39, 0.51) 0.806
ICTP
Velocityn  1.16 ( 2.62, 0.30) 0.119  1.16 ( 2.62, 0.30) 0.119  1.61 ( 3.34, 0.11) 0.067
Acceleration 5.93 (1.54, 10.31) 0.008 5.93 (1.54, 10.31) 0.008 10.24 (4.99, 15.49) o0.001
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
BoP
Velocityw 1.51 (1.08, 2.10) 0.016 1.49 (1.07, 2.08) 0.017 1.39 (0.97, 1.99) 0.075
Accelerationw 0.65 (0.25, 1.70) 0.380 0.66 (0.25, 1.71) 0.389 1.39 (0.48, 4.07) 0.546
Plaque
Velocityw 1.15 (0.79, 1.69) 0.464 1.14 (0.79, 1.65) 0.484 1.65 (1.07, 2.57) 0.025
Accelerationw 1.55 (0.53, 4.51) 0.423 1.50 (0.53, 4.26) 0.442 6.28 (1.80, 21.84) 0.004
nN 5 3208 (not 8428) as GCF data are not available for all treated teeth.
wEstimates are odds ratios.
Diff, estimated overall differences between treatment and placebo groups across the study period; ICTP, carboxyterminal telopeptide of type I collagen
as ln(pg/site); OR, estimated overall odds ratio in the differences between treatment and placebo groups across the study period; CI, confidence interval;
velocity, difference between groups in change in outcome per month; acceleration, difference between groups in rate of change in outcome per month;
Model 1, no adjustment for smoking exposure; Model 2, adjustment for baseline smoking exposure (number of cigarettes per day, number of years as a
smoker); Model 3, adjustment for occasion-specific baseline smoking exposure (cotinine, CO%); BoP, bleeding on probing; CAL, clinical attachment
level.
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significantly greater in the treatment
group; Model 3: difference in mean
velocity of REC 5 0.18 mm/month
(95% CI 5 0.03, 0.33; p 5 0.021). How-
ever, there was no notable acceleration
of this divergence; Model 3: difference
in mean acceleration of REC 5
0.06 mm/month2 (95% CI 5  0.39
0.51; p 5 0.806).
Similar trends were observed for
ICTP as for REC, with patterns of
change in the opposite direction. That
is, with or without adjustment for base-
line smoking exposure, ICTP showed
a slightly greater velocity of reduction
in the treatment group compared with
the control group, although not formally
significant; Models 1 and 2: differ-
ence in mean velocity of ln(ICTP) 5
 1.16 mm/month2 (95% CI 5  2.62,
0.30; p 5 0.119). However, divergence
between groups was growing and sig-
nificant; Models 1 and 2: difference in
mean acceleration of ln(ICTP) 5 5.93
mm/month2 (95% CI 5 1.54, 10.31;
p 5 0.008). When adjustment was
made for occasion-specific smoking
exposure (Model 3), the velocity of
change between groups became border-
line significant; Model 3: difference in
mean velocity of ln(ICTP) 5  1.61
mm/month (95% CI 5  3.34, 0.11;
p 5 0.067). Furthermore, the divergence
was accelerating even more rapidly;
Model 3: difference in mean accelera-
tion of ln(ICTP) 5 10.24 mm/month2
(95% CI 5 4.99, 15.49; po0.001).
For BoP and plaque, logistic models
gave rise to model coefficients inter-
preted as odds ratios (ORs), which are
on a non-linear scale, as the OR is
multiplicative (not additive). Thus, for
BoP, there were significantly elevated
odds of BoP in the treatment group
compared with the control group, with
or without adjustment for baseline
smoking experience (Models 1 and 2),
and although the interaction between
group and acceleration was not signifi-
cant, the model nevertheless suggests
that divergence between groups was
increasing. When adjustment was made
for occasion-specific smoking exposure
(Model 3), the contrast between groups
is attenuated towards the null. There
were generally greater odds of plaque
among the treatment group than the
control group, although this was not
statistically significant unless adjust-
ment was made for occasion-specific
smoking exposure.
These findings indicate substantial
differences in the estimated differences
in the patterns of change in the various
outcomes (i.e. increasing or decreasing
divergence between groups) when
adjusting for occasion-specific expo-
sures of smoking (COT, CO) compared
with either no adjustment or adjustment
for baseline smoking exposures (number
of cigarettes per day, number of years as
a smoker). Adjustment for baseline
smoking exposures has virtually no
impact on the estimated differences
between treatment and control groups
in the changes in outcome throughout
the study period.
Adverse events
Adverse events were reported by five
subjects, all in the placebo group: two
were at 1 month follow-up and 3- at 6-
month follow-up. These were judged not
to be adverse reactions related to the
medication and included pulpal pro-
blems in three subjects and periodontal
problems in two subjects. Data on
adverse events were missing from two
patients who did not return following
treatment (one in each group) and from
six patients at one study visit.
Compliance
Full data were available for 27 subjects
(Fig. 4). Those missing 10 or less tablets
out of a total of approximately 180
tablets were 11/13 patients in the place-
bo group and 12/14 in the test group.
Discussion
Statement of principal findings
This study has shown that an interven-







































Fig. 3. Change in probing depth level with time (mean1SD).
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effect clinical changes following non-
surgical periodontal therapy in smokers.
The final improvements were no differ-
ent between the test and control groups,
but multilevel modelling (MLM)
revealed different trajectories for clin-
ical changes. In other words, the end-
point of clinical healing was similar for
both experimental groups; however, the
rate of improvement was greater for the
test group. No differences regarding
absolute CAL change or GCF ICTP
were evident.
Conventional statistics and MLM
have very different methodologies and
ask different questions of the data. The
MLM approach was not selected as an
attempt to find a difference between
groups at all costs. Rather, the use of
MLM was selected, a priori, to examine
whether accounting for differences
between sites within patients and at
different visits might reveal differences
in response to the intervention.
The contrast between the multilevel
time-series models either with or with-
out adjustment for baseline smoking
exposures compared with adjustment
for occasion-specific smoking exposures
could be a chance finding, although it is
consistent across all outcomes modelled
except CAL and ICTP. Therefore, it is
likely that baseline smoking exposure
assessments had little or no impact,
whereas occasion-specific smoking
exposure assessments did. This might
be because the baseline assessments of
number of cigarettes per day and num-
ber of years as a smoker are too impre-
cise or are too inaccurate (error-prone,
where self-report is unreliable and may
be biased), or both. In contrast, the
occasion-specific measures of COT and
CO may yield a more precise reflection
of smoking habits and are free from
responder bias. We are currently exam-
ining relationships between self-
reported smoking status and biochem-
ical values and these data will be
reported in a further publication.
No difference could be shown for
GCF ICTP levels between groups in
this study. Previous investigations have
demonstrated that LDD potently reduces
ICTP levels in patients with previously
untreated, severe disease and in patients
receiving surgery combined with the
drug (Golub et al. 1997, Gapski et al.
2004). However, in patients with pre-
viously treated periodontitis receiving
SRP with or without locally delivered
minocycline (another TCN analogue
similar to doxycyline), minimal and
transient reductions in GCF ICTP were
demonstrated (Al-Shammari et al. 2001,
Oringer et al. 2002). These data suggest
a need to continue medication indefi-
nitely if suppression of ICTP levels is
desirable. The lack of effect in this study
might indicate that smoking affects the
pathways involved in bone turnover,
reducing such targeting. It is interesting
that another study, also exclusively in
smokers, did not find an effect on ICTP
when using the antibiotic azithromycin
as an adjunct to non-surgical periodontal
therapy (Mascarenhas et al. 2005).
While ICTP levels in this study
appeared to be lower than in other
studies (Al-Shammari et al. 2001, Gaps-
ki et al. 2004, Mascarenhas et al. 2005),
the differences may be more apparent
than real. The geometric mean was
selected as the appropriate statistic to
summarize the data as it was highly
skewed. This representation results in
low summary values although the same
protocol for collection, storage and
assay was used compared with other
studies. For comparison, the arithmetic
mean values (95% CI) for ICTP at
baseline were: test group 50.45 ng/site
( 56.66, 157.56), control group
63.66 ng/site ( 106.49, 233.81).
It is interesting to note the high
proportion of sites with BoP in smokers
throughout the study. While it has been
suggested that smoking reduced BoP, a
systematic review of the effects of
smoking on the response to non-surgical
therapy could not find a difference in
levels of the parameter (Labriola et al.
2005).
Strengths and weaknesses of the study
The study failed to show any significant
differences between treatment arms
using aggregate (standard subject-
based) analyses because the observed
treatment effects were smaller than ori-
ginally anticipated when powering the
study. In contrast, it was anticipated and
indeed demonstrated that a multilevel
(site-based) analysis would have suffi-
cient power for the study of this size and
thus be able to reveal statistically sig-
nificant treatment effects (whether clini-
cally significant or not). Although
optimum statistical power is generally
achieved using ANCOVA, the multilevel
extension to this was questionable in
view of subjects and not teeth or sites
being randomized, as this brought into
question the reliability of balanced base-
line mean outcomes. Multilevel ana-
lyses might therefore yield greater
power than aggregate analyses, although
care must be exercised in favouring the
multilevel time-series approach to a
multilevel ANCOVA approach when ran-
domization is not applicable to the low-
est-level unit (sites in this instance).
Strengths and weaknesses in relation to
other studies
A strength of this study was that it was
designed from the outset to investigate
the effect of the experimental interven-
tion on smokers. This contrasts with
other studies that have used analysis of
smoking subgroups in clinical trials of
non-surgical therapy with LDD where
both smokers and non-smokers were
recruited (Preshaw et al. 2005). Sub-
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Fig. 4. Distribution of compliance with study medication.
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to the presence of unknown confounders
and the possibility of chance of statisti-
cally significant results (Brookes et al.
2001). Therefore, the results of this
study should provide more reliable
evidence.
A further strength of this study was
the minimization of bias. Allocation was
concealed from those recruited for a
study, thereby eliminating selection
bias. The patient, examiner, caregiver
and statistician were all masked to allo-
cation until the analysis was complete.
Regarding withdrawals, all subjects ran-
domized to treatment contributed to the
analysis using intention-to-treat meth-
ods. To minimize treatment-related
effects, compliance with medication
was reinforced and monitored. Compli-
ance was good, although the data are
based on self-reported data. Studies on
smokers have shown increased losses to
follow-up (Nasry et al. 2006), and the
use of long-term medication for chronic
conditions has been problematic (Roter
et al. 1998). As a result of minimization
of bias, the estimate of treatment effect
should be reliable.
A limitation of this study was the
relatively small number of participants.
The study was powered adequately for
conventional statistics for the primary
outcome, but may not have been ade-
quately powered for secondary out-
comes. The efficiency gained by using
ML should have compensated for this
especially as the N for MLM was esti-
mated as 48000. However, more
studies are needed to explore the use of
ML on clinical trials in periodontology.
Meaning of the study: possible
explanations and implications for
clinicians and policymakers
This study does not provide evidence to
support the use of LDD as an adjunct
to non-surgical periodontal therapy in
smokers. While differences in trajectory
between the test and control groups
were shown for clinical parameters, the
value of this difference to clinical prac-
tice is not known currently (Nevins et al.
2005).
Upregulation of inflammation re-
mains a compelling hypothesis to ex-
plain, at least in part, the reduced
healing response in smokers (Palmer
et al. 1999b, Kinane & Chestnutt
2000). The failure to show an adjunctive
effect in this study might indicate that
either the intervention was ineffective in
achieving host modulation in smokers or
that other pathways or mechanisms must
also be targeted to achieve a therapeutic
effect. Further research to investigate
mechanisms to explain the impaired
healing response in smokers is therefore
warranted and it is hoped that this will
lead to improved strategies for mana-
ging periodontal disease in smokers. In
addition, tobacco use cessation should
continue to be of paramount importance
in such individuals.
Conclusions
Non-surgical periodontal therapy in
smokers can produce a substantial
improvement in periodontal health.
However, there is no evidence to sup-
port the use of LDD as an adjunct to
non-surgical therapy in smokers. Quit-
ting tobacco use continues to be of
fundamental importance in improving
the periodontal health of these indivi-
duals. Multilevel modelling shows great
promise as an analytical tool for perio-
dontal clinical trials and should be
examined in a wide variety of trial
designs for its contribution to data
analysis.
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Scientific rationale for the study:
Periodontitis is less responsive to
non-surgical therapy in smokers
than non-smokers and this may be
partly due to increased inflammation
in smokers. The rationale for this
study was to test whether chemically
modifying inflammation and tissue
breakdown using LDD at the same
time as non-surgical periodontal ther-
apy in smokers might be beneficial.
Principal findings: Despite improve-
ments in periodontal health, no addi-
tional benefit was demonstrated com-
paring those subjects who received
the test drug with the identical
placebo.
Practical implications: Conventional
periodontal therapy improves the
periodontal health of smokers. Quit-
ting tobacco use continues to be a
high priority.
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